Initial in vivo evaluation of the DexAide right ventricular assist device

Yoshio Ootaki, Keiji Kamohara, Masatoshi Akiyama, Firas Zahr, Michael W. Kopcak, Raymond Dessoffy, Alex Massiello, David Horvath, Ji Feng Chen, Stephen Benefit, Leonard A R Golding, Kiyotaka Fukamachi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite the increasing use of left ventricular assist devices for patients with end-stage congestive heart failure, no implantable, centrifugal right ventricular assist devices (RVADs) are available for those patients with significant right ventricular failure. The DexAide RVAD was developed to provide an implantable RVAD option to surgeons. The aim of this study was to evaluate pump performance in an acute in vivo model. The DexAide RVAD, developed as a modified CorAide left ventricular assist device, was implanted between the right ventricle and the pulmonary artery in four healthy calves. Pump speed was varied from 1800 rpm to 3600 rpm. RVAD performance was analyzed acutely at baseline and under conditions of low circulating volume, high contractility, high pulmonary arterial pressure, vasodilation, and low contractility. Pump flow was well maintained even under conditions of high pulmonary arterial pressure and vasodilation, with the exception of low circulating volume. Under all conditions, pulmonary arterial pressures were not affected by changing pump speed. The DexAide RVAD demonstrated acceptable hemodynamic characteristics for use as an implantable RVAD in the initial acute studies. Further studies are ongoing to examine the biocompatibility of the pump under chronic conditions.

Original languageEnglish (US)
Pages (from-to)739-742
Number of pages4
JournalASAIO Journal
Volume51
Issue number6
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Heart-Assist Devices
Pumps
Left ventricular assist devices
Arterial Pressure
Hemodynamics
Vasodilation
Lung
Biocompatibility
Pulmonary Artery
Heart Ventricles
Heart Failure

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering

Cite this

Ootaki, Y., Kamohara, K., Akiyama, M., Zahr, F., Kopcak, M. W., Dessoffy, R., ... Fukamachi, K. (2005). Initial in vivo evaluation of the DexAide right ventricular assist device. ASAIO Journal, 51(6), 739-742. https://doi.org/10.1097/01.mat.0000187399.46756.fc

Initial in vivo evaluation of the DexAide right ventricular assist device. / Ootaki, Yoshio; Kamohara, Keiji; Akiyama, Masatoshi; Zahr, Firas; Kopcak, Michael W.; Dessoffy, Raymond; Massiello, Alex; Horvath, David; Chen, Ji Feng; Benefit, Stephen; Golding, Leonard A R; Fukamachi, Kiyotaka.

In: ASAIO Journal, Vol. 51, No. 6, 11.2005, p. 739-742.

Research output: Contribution to journalArticle

Ootaki, Y, Kamohara, K, Akiyama, M, Zahr, F, Kopcak, MW, Dessoffy, R, Massiello, A, Horvath, D, Chen, JF, Benefit, S, Golding, LAR & Fukamachi, K 2005, 'Initial in vivo evaluation of the DexAide right ventricular assist device', ASAIO Journal, vol. 51, no. 6, pp. 739-742. https://doi.org/10.1097/01.mat.0000187399.46756.fc
Ootaki, Yoshio ; Kamohara, Keiji ; Akiyama, Masatoshi ; Zahr, Firas ; Kopcak, Michael W. ; Dessoffy, Raymond ; Massiello, Alex ; Horvath, David ; Chen, Ji Feng ; Benefit, Stephen ; Golding, Leonard A R ; Fukamachi, Kiyotaka. / Initial in vivo evaluation of the DexAide right ventricular assist device. In: ASAIO Journal. 2005 ; Vol. 51, No. 6. pp. 739-742.
@article{72b1fdfc86944a5aaf676d93e72bd6bb,
title = "Initial in vivo evaluation of the DexAide right ventricular assist device",
abstract = "Despite the increasing use of left ventricular assist devices for patients with end-stage congestive heart failure, no implantable, centrifugal right ventricular assist devices (RVADs) are available for those patients with significant right ventricular failure. The DexAide RVAD was developed to provide an implantable RVAD option to surgeons. The aim of this study was to evaluate pump performance in an acute in vivo model. The DexAide RVAD, developed as a modified CorAide left ventricular assist device, was implanted between the right ventricle and the pulmonary artery in four healthy calves. Pump speed was varied from 1800 rpm to 3600 rpm. RVAD performance was analyzed acutely at baseline and under conditions of low circulating volume, high contractility, high pulmonary arterial pressure, vasodilation, and low contractility. Pump flow was well maintained even under conditions of high pulmonary arterial pressure and vasodilation, with the exception of low circulating volume. Under all conditions, pulmonary arterial pressures were not affected by changing pump speed. The DexAide RVAD demonstrated acceptable hemodynamic characteristics for use as an implantable RVAD in the initial acute studies. Further studies are ongoing to examine the biocompatibility of the pump under chronic conditions.",
author = "Yoshio Ootaki and Keiji Kamohara and Masatoshi Akiyama and Firas Zahr and Kopcak, {Michael W.} and Raymond Dessoffy and Alex Massiello and David Horvath and Chen, {Ji Feng} and Stephen Benefit and Golding, {Leonard A R} and Kiyotaka Fukamachi",
year = "2005",
month = "11",
doi = "10.1097/01.mat.0000187399.46756.fc",
language = "English (US)",
volume = "51",
pages = "739--742",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Initial in vivo evaluation of the DexAide right ventricular assist device

AU - Ootaki, Yoshio

AU - Kamohara, Keiji

AU - Akiyama, Masatoshi

AU - Zahr, Firas

AU - Kopcak, Michael W.

AU - Dessoffy, Raymond

AU - Massiello, Alex

AU - Horvath, David

AU - Chen, Ji Feng

AU - Benefit, Stephen

AU - Golding, Leonard A R

AU - Fukamachi, Kiyotaka

PY - 2005/11

Y1 - 2005/11

N2 - Despite the increasing use of left ventricular assist devices for patients with end-stage congestive heart failure, no implantable, centrifugal right ventricular assist devices (RVADs) are available for those patients with significant right ventricular failure. The DexAide RVAD was developed to provide an implantable RVAD option to surgeons. The aim of this study was to evaluate pump performance in an acute in vivo model. The DexAide RVAD, developed as a modified CorAide left ventricular assist device, was implanted between the right ventricle and the pulmonary artery in four healthy calves. Pump speed was varied from 1800 rpm to 3600 rpm. RVAD performance was analyzed acutely at baseline and under conditions of low circulating volume, high contractility, high pulmonary arterial pressure, vasodilation, and low contractility. Pump flow was well maintained even under conditions of high pulmonary arterial pressure and vasodilation, with the exception of low circulating volume. Under all conditions, pulmonary arterial pressures were not affected by changing pump speed. The DexAide RVAD demonstrated acceptable hemodynamic characteristics for use as an implantable RVAD in the initial acute studies. Further studies are ongoing to examine the biocompatibility of the pump under chronic conditions.

AB - Despite the increasing use of left ventricular assist devices for patients with end-stage congestive heart failure, no implantable, centrifugal right ventricular assist devices (RVADs) are available for those patients with significant right ventricular failure. The DexAide RVAD was developed to provide an implantable RVAD option to surgeons. The aim of this study was to evaluate pump performance in an acute in vivo model. The DexAide RVAD, developed as a modified CorAide left ventricular assist device, was implanted between the right ventricle and the pulmonary artery in four healthy calves. Pump speed was varied from 1800 rpm to 3600 rpm. RVAD performance was analyzed acutely at baseline and under conditions of low circulating volume, high contractility, high pulmonary arterial pressure, vasodilation, and low contractility. Pump flow was well maintained even under conditions of high pulmonary arterial pressure and vasodilation, with the exception of low circulating volume. Under all conditions, pulmonary arterial pressures were not affected by changing pump speed. The DexAide RVAD demonstrated acceptable hemodynamic characteristics for use as an implantable RVAD in the initial acute studies. Further studies are ongoing to examine the biocompatibility of the pump under chronic conditions.

UR - http://www.scopus.com/inward/record.url?scp=33644876728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644876728&partnerID=8YFLogxK

U2 - 10.1097/01.mat.0000187399.46756.fc

DO - 10.1097/01.mat.0000187399.46756.fc

M3 - Article

C2 - 16340360

AN - SCOPUS:33644876728

VL - 51

SP - 739

EP - 742

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 6

ER -